(Translated by https://www.hiragana.jp/)
氨柔比星 - 维基百科,自由的百科全书 とべ转到内容ないよう

氨柔ほし

维基百科ひゃっか自由じゆうてき百科ひゃっかぜん
氨柔ほし
臨床りんしょう資料しりょう
AHFS/Drugs.comくに际药ひん名称めいしょう
给药みちIV
ATC碼
法律ほうりつ規範きはん狀態じょうたい
法律ほうりつ規範きはん
  • 处方药(-only)
识别しんいき
  • (7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
CASごう110267-81-7  ☒N
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox DashboardえいCompTox Chemicals Dashboard (EPA)
化学かがくしんいき
化学かがくしきC25H25NO9
尔质りょう483.47 g·mol−1
3D模型もけいJSmolえいJSmol
  • O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@](C(=O)C)(N)C[C@@H]5O[C@@H]4OC[C@@H](O)[C@@H](O)C4
  • InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1 checkY
  • Key:VJZITPJGSQKZMX-XDPRQOKASA-N checkY

氨柔ほしINN:amrubicin;开发だいごうSM-5887一种用于治疗肺癌はいがんてき蒽环类药ぶつ[1]它自2002ねんおこりゆかり住友すみともせい以商品名ひんめいCalsedざい日本にっぽん销售。[2]

氨柔ほしどおり抑制よくせいつぶせ扑异构酶II发挥作用さよう,并在临床试验ちゅうあずかつぶせ扑替やすしつぶせ扑异构酶I抑制よくせい剂)进行りょう较。[3][4]

它还研究けんきゅうよう于治疗膀胱ぼうこうがん[5]胃癌いがん[6]

氨柔ほしだいいち个通过从头合成ごうせいてき蒽环类衍生物せいぶつゆかり住友すみとも化学かがくてき科学かがく于1989ねんくび发表。[7]

参考さんこう资料[编辑]

  1. ^ Ueoka H, Ohnoshi T, Kimura I. [New anthracycline analogues in the treatment of lung cancer]. Gan to Kagaku Ryoho. November 1992, 19 (13): 2146–9. PMID 1332624 にち语). 
  2. ^ Sumitomo Pharmaceuticals Co., Ltd. CALSED for Injection (English) (PDF). 2003 [2008-08-17].  [失效しっこう連結れんけつ]
  3. ^ Celgene Corporation. Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer. 2008 [2009-07-10]. (原始げんし内容ないようそん档于2013-01-19). 
  4. ^ Medical News Today. Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer. 2007 [2009-07-10]. 
  5. ^ Ohmori H, Tsushima T, Kobashi K. [Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]. Gan to Kagaku Ryoho. April 1996, 23 (5): 601–6. PMID 8678519 にち语). 
  6. ^ Tsushima K, Sakata Y, Munakata A, et al. [A phase II study of SM-5887 for advanced gastric cancer]. Gan to Kagaku Ryoho. June 1991, 18 (7): 1151–4. PMID 1647150 にち语). 
  7. ^ Hanada M. Amrubicin, Chapter 6 in Case Studies in Modern Drug Discovery and Development. Eds. Huang X and Aslanian RG. John Wiley & Sons, 2012 ISBN 9780470601815 P 106